Rybrevant
| Chemical Name | amivantamab-vmjw |
| Dosage Form | Injection (intravenous; 350 mg/7 mL) |
| Drug Class | Monoclonal antibodies |
| System | Respiratory |
| Company | Janssen Biotech |
| Approval Year | 2021 |
Indication
- For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.